SRL4 Antibody

What is SSTR4 and what is its biological significance?

SSTR4 (Somatostatin Receptor Type 4) is a G protein-coupled receptor that binds somatostatin. Also known as SS4-R, SS4R, or SST4, this receptor has a molecular mass of approximately 41 kDa . SSTR4's activity is mediated by G proteins which inhibit adenylyl cyclase. The receptor is functionally coupled not only to inhibition of adenylate cyclase but also to activation of both arachidonate release and the mitogen-activated protein (MAP) kinase cascade .

One of SSTR4's most significant functions is mediating the antiproliferative action of somatostatin in tumor cells, making it an important target in cancer research . This receptor's signaling pathways influence numerous physiological processes including hormone secretion, neurotransmission, and cell proliferation.

What are the standard applications for SSTR4 antibodies in research?

SSTR4 antibodies are versatile research tools with several established applications:

• Western Blotting (WB): For detecting and quantifying SSTR4 protein levels in tissue or cell lysates .

• Immunohistochemistry on Paraffin Sections (IHC-P): For visualizing SSTR4 distribution in fixed tissue specimens .

• Immunocytochemistry/Immunofluorescence (ICC/IF): For examining cellular and subcellular localization of SSTR4 in cultured cells .

• Receptor Signaling Studies: For investigating SSTR4's role in somatostatin-mediated signal transduction pathways.

• Cancer Research: For studying antiproliferative mechanisms in various tumor models.

When selecting an SSTR4 antibody, researchers should consider the specific experimental requirements, including species reactivity (commonly available for human and mouse samples) and validated applications .

How does SSTR4 compare structurally and functionally to other somatostatin receptors?

SSTR4 belongs to the somatostatin receptor family (SSTR1-5), which share structural similarities as G protein-coupled receptors but exhibit distinct functional properties:

Unlike other somatostatin receptors, SSTR4 shows particular prominence in mediating anti-inflammatory responses and neuroprotective effects. When designing experiments involving multiple somatostatin receptors, researchers must carefully validate antibody specificity to avoid cross-reactivity issues between these structurally related proteins.

What are the optimal protocols for using SSTR4 antibodies in immunocytochemistry and immunofluorescence?

For successful immunofluorescence staining with SSTR4 antibodies, the following optimized protocol is recommended based on validated approaches:

• Cell Preparation:

  • Culture cells to 70% confluence on appropriate coverslips or chamber slides .

  • Fix cells with 4% paraformaldehyde for 10 minutes at room temperature .

  • Permeabilize with 0.1% Triton X-100 for 10 minutes .

  • Block with 2% BSA for 1 hour at room temperature to reduce non-specific binding .

• Antibody Incubation:

  • Dilute primary SSTR4 antibody to an appropriate concentration (typically 1:250 in 0.1% BSA solution) .

  • Incubate cells with primary antibody for 1-2 hours at room temperature or overnight at 4°C.

  • Wash thoroughly with PBS (3-5 times, 5 minutes each).

  • Incubate with appropriate fluorophore-conjugated secondary antibody for 1 hour at room temperature.

• Visualization:

  • Counterstain nuclei with DAPI if desired.

  • Mount slides using an anti-fade mounting medium.

  • Analyze using confocal or fluorescence microscopy.

Successful SSTR4 staining typically reveals both membrane and cytoplasmic localization patterns. Critical controls should include primary antibody omission and ideally, SSTR4 knockdown/knockout samples.

What validation strategies should be employed to confirm SSTR4 antibody specificity?

Thorough validation is essential for ensuring SSTR4 antibody specificity and reliable experimental outcomes. Recommended validation approaches include:

• Western Blot Analysis:

  • Verify a single band at the expected molecular weight (~41 kDa) .

  • Compare expression in tissues/cells known to express SSTR4 versus those with minimal expression.

  • Use positive control lysates with confirmed SSTR4 expression.

• Peptide Competition Assays:

  • Pre-incubate the antibody with the immunizing peptide (typically from the C-terminus region, amino acids 350 to C-terminus in human SSTR4) .

  • Specific binding should be abolished or significantly reduced when the antibody is neutralized.

• Genetic Controls:

  • Test antibody in SSTR4 knockout/knockdown models compared to wild-type controls.

  • Use overexpression systems to confirm signal increase with elevated SSTR4 levels.

• Cross-Reactivity Assessment:

  • Evaluate potential cross-reactivity with other somatostatin receptor subtypes.

  • Test in systems expressing other SSTR subtypes but not SSTR4.

• Multi-technique Concordance:

  • Confirm consistent SSTR4 detection patterns across multiple techniques (WB, IHC, ICC).

  • Use multiple antibodies targeting different SSTR4 epitopes when possible.

Comprehensive validation not only ensures experimental reliability but also helps identify optimal conditions for each specific application.

How can researchers troubleshoot common issues with SSTR4 antibody experiments?

When working with SSTR4 antibodies, researchers frequently encounter several technical challenges. Here are methodological solutions for common problems:

For immunofluorescence specifically, poor SSTR4 membrane localization may occur due to receptor internalization during fixation. Testing different fixation methods (paraformaldehyde vs. methanol) and times can help preserve authentic receptor distribution.

How can SSTR4 antibodies be utilized to study receptor-mediated signaling pathways?

SSTR4 antibodies enable sophisticated analysis of receptor-mediated signaling through several advanced methodological approaches:

• Co-immunoprecipitation (Co-IP) Studies:

  • Use validated SSTR4 antibodies to precipitate the receptor complex from cell lysates.

  • Identify novel binding partners through mass spectrometry analysis.

  • Investigate how ligand stimulation alters the composition of SSTR4 protein complexes.

  • Technical consideration: Use mild detergents (0.5-1% NP-40 or CHAPS) to preserve protein-protein interactions.

• Spatial Signaling Analysis:

  • Employ dual immunofluorescence with SSTR4 antibodies and phospho-specific antibodies against downstream effectors (p-ERK, p-STAT3).

  • Quantify co-localization coefficients to measure activation patterns.

  • Apply proximity ligation assays (PLA) to visualize specific SSTR4 interactions with signaling components with single-molecule resolution.

• Receptor Trafficking Studies:

  • Use SSTR4 antibodies to track receptor internalization kinetics after agonist stimulation.

  • Quantify membrane/cytoplasmic/endosomal distribution following various treatments.

  • Combine with markers of endocytic compartments to map trafficking routes.

• Functional Blocking Studies:

  • Apply function-blocking SSTR4 antibodies to selectively inhibit this receptor subtype.

  • Measure impact on downstream signaling events (adenylyl cyclase inhibition, MAP kinase activation).

  • Compare with small molecule antagonists to validate receptor-specific effects.

These methodologies enable researchers to dissect the specific contributions of SSTR4 to complex somatostatin signaling networks and identify potential therapeutic targets.

What role does SSTR4 play in cancer research and how can antibodies facilitate these investigations?

SSTR4 has significant relevance in cancer research, particularly through its antiproliferative functions . SSTR4 antibodies enable several sophisticated approaches to investigate its role in tumor biology:

• Expression Profiling in Tumor Specimens:

  • Apply SSTR4 antibodies in IHC analyses of tumor tissue microarrays.

  • Correlate expression patterns with clinicopathological parameters and patient outcomes.

  • Compare expression in tumor versus adjacent normal tissue to identify altered regulation.

• Mechanism of Antiproliferative Action:

  • Use SSTR4 antibodies to investigate how this receptor mediates antiproliferative effects in tumor cells .

  • Examine downstream signaling components (MAP kinase pathway, cell cycle regulators).

  • Evaluate receptor phosphorylation states in response to somatostatin analogs.

• Therapeutic Target Validation:

  • Develop and characterize therapeutic antibodies targeting SSTR4.

  • Create antibody-drug conjugates for targeted delivery to SSTR4-expressing tumors.

  • Evaluate anti-tumor efficacy in preclinical models with confirmed SSTR4 expression.

• Resistance Mechanism Investigation:

  • Analyze SSTR4 expression, localization, and phosphorylation in treatment-resistant versus sensitive tumors.

  • Identify alterations in receptor trafficking or signaling that contribute to therapeutic resistance.

  • Develop combination strategies to overcome resistance based on mechanistic insights.

The application of highly specific SSTR4 antibodies in these research contexts may reveal new opportunities for cancer diagnosis and targeted therapy development.

How are emerging antibody technologies being applied to SSTR4 research?

Innovative antibody engineering approaches are expanding the capabilities of SSTR4 research tools:

• Synthetic Anti-RNA Antibody Derivatives:

  • Adaptation of sarabody technology (synthetic anti-RNA antibodies) for visualization of SSTR4 mRNA in living cells .

  • These antibody derivatives can be expressed as GFP fusion proteins to track RNA localization .

  • Potential application: Simultaneous visualization of SSTR4 mRNA and protein to study expression dynamics.

• Rationally Designed Antibodies:

  • Computational design methods to create antibodies targeting specific SSTR4 epitopes with enhanced specificity .

  • Complementarity determining region (CDR) engineering to optimize binding properties .

  • Application of diversified CDR libraries and selection methods to develop epitope-specific probes .

• Novel Antibody Formats:

  • Development of single-chain variable fragments (scFvs) against SSTR4 for improved tissue penetration .

  • Creation of bispecific antibodies targeting SSTR4 and other relevant markers simultaneously.

  • Application of antibody fragments as intracellular expression systems for tracking SSTR4 in living cells.

• Advanced Analytical Techniques:

  • Implementation of mass photometry, native mass spectrometry, and size exclusion chromatography multi-angle light scattering (SEC-MALS) for precise characterization of antibody-SSTR4 interactions .

  • These methods enable accurate determination of binding stoichiometries and affinities .

  • Particularly valuable for analyzing heavily glycosylated forms of receptors like SSTR4 .

These emerging technologies are expanding the repertoire of SSTR4 research tools beyond traditional antibody applications, enabling more sophisticated investigations of receptor biology and function.

What strategies can address cross-reactivity concerns with SSTR4 antibodies?

Cross-reactivity between SSTR4 and other somatostatin receptors presents a significant challenge due to sequence homology. Methodological approaches to minimize this issue include:

• Epitope-Focused Selection:

  • Choose antibodies targeting regions with minimal sequence homology to other SSTR subtypes.

  • C-terminal directed antibodies often provide better specificity, particularly those targeting amino acids 350 to the C-terminus of human SSTR4 .

  • Evaluate sequence alignments before selecting antibodies for multi-receptor studies.

• Comprehensive Validation:

  • Implement stringent validation using receptor-specific knockout or knockdown models.

  • Perform peptide competition assays with peptides from SSTR4 and other SSTR subtypes.

  • Validate antibody specificity across multiple techniques (WB, IHC, IF) to ensure consistent results.

• Absorption Controls:

  • Pre-absorb antibodies with recombinant proteins or peptides from other SSTR subtypes.

  • Systematically test absorption with peptides from each SSTR subtype to identify potential cross-reactivity.

  • Include appropriate controls: specific peptide absorption (negative control) and non-relevant peptide absorption (positive control).

• Multi-Antibody Approach:

  • Use multiple antibodies targeting different SSTR4 epitopes.

  • Concordant results across different antibodies increase confidence in specificity.

  • When discrepancies arise, investigate which antibody provides more reliable specificity.

These methodological approaches significantly enhance the reliability of SSTR4 detection in complex biological systems expressing multiple somatostatin receptor subtypes.

How should researchers optimize SSTR4 antibody conditions for different experimental systems?

Optimization of SSTR4 antibody protocols is essential for reliable results across different experimental systems:

• Western Blotting Optimization:

  • Sample preparation: Test different lysis buffers (RIPA vs. NP-40 vs. Triton X-100) to maximize SSTR4 extraction.

  • Blocking conditions: Compare 5% milk vs. 5% BSA (BSA often preferred for phosphorylation studies).

  • Dilution optimization: Perform antibody titration (typically 1:500-1:2000) to determine optimal signal-to-noise ratio.

  • Membrane transfer: For this 41 kDa protein, optimize transfer conditions (wet transfer at 30V overnight often yields best results) .

• Immunohistochemistry Parameters:

  • Fixation comparison: Test 10% neutral buffered formalin vs. 4% paraformaldehyde vs. methanol fixation.

  • Antigen retrieval: Compare citrate buffer (pH 6.0) vs. EDTA buffer (pH 9.0) and microwave vs. pressure cooker methods.

  • Detection systems: Evaluate standard ABC methods vs. polymer-based detection vs. tyramide signal amplification.

  • Titration range: Test primary antibody dilutions between 1:100-1:500 for optimal staining.

• Immunofluorescence Refinement:

  • Fixation duration: Compare 10-minute vs. 20-minute paraformaldehyde fixation to preserve membrane localization .

  • Permeabilization conditions: Test 0.1% Triton X-100 vs. 0.5% saponin vs. 0.1% digitonin for optimal epitope access .

  • Blocking intensity: Evaluate 2% BSA vs. 5% normal serum vs. commercial blocking reagents .

  • Mounting media: Compare regular vs. hardening vs. anti-fade formulations for signal preservation.

• Cell-Type Specific Considerations:

  • Neuronal cells: May require gentler fixation to preserve receptor localization.

  • Primary cells vs. cell lines: Primary cells often require higher antibody concentrations.

  • Transfected vs. endogenous expression: Overexpression systems may require more dilute antibody solutions.

Systematic optimization using positive controls with known SSTR4 expression ensures reliable detection across experimental systems.

What quality control measures should be implemented when using SSTR4 antibodies?

Rigorous quality control is essential for generating reproducible, reliable data with SSTR4 antibodies. Key methodological approaches include:

• Antibody Validation Documentation:

  • Maintain comprehensive records of validation experiments for each antibody lot.

  • Document specificity tests including western blots, peptide competitions, and knockout controls.

  • Create an antibody validation report accessible to all laboratory members.

• Positive and Negative Controls:

  • Establish a panel of positive controls (tissues/cells with confirmed SSTR4 expression).

  • Include negative controls in each experiment:

    • Primary antibody omission

    • Isotype control antibody

    • Known SSTR4-negative samples

    • Peptide-neutralized antibody controls

• Technical Standardization:

  • Develop detailed standard operating procedures (SOPs) for each application.

  • Specify critical parameters: antibody dilution, incubation time/temperature, washing conditions.

  • Standardize image acquisition settings for fluorescence applications.

  • Implement quantitative analysis methods with defined thresholds.

• Reagent Management:

  • Track antibody lot numbers and maintain lot consistency for ongoing projects.

  • Aliquot antibodies upon receipt to minimize freeze-thaw cycles.

  • Regularly test antibody performance using standardized samples.

  • Establish maximum storage times and conditions for working dilutions.

• Data Reproducibility Assessment:

  • Periodically repeat key experiments with new antibody lots.

  • Conduct inter-operator reproducibility tests for critical assays.

  • Compare results across different detection methods when possible.

Implementation of these quality control measures significantly enhances data reliability and facilitates troubleshooting when unexpected results occur.

How might synthetic antibody engineering advance SSTR4 research?

Synthetic antibody engineering represents a promising frontier for developing next-generation SSTR4 research tools:

• CDR Engineering for Enhanced Specificity:

  • Application of computational design methods to create antibodies with precise epitope targeting .

  • Generation of CDR-diversified libraries for selecting SSTR4-specific binding domains .

  • Development of antibodies that can distinguish between different conformational states of SSTR4.

• Novel Antibody Formats:

  • Creation of single-domain antibodies (nanobodies) against SSTR4 for improved tissue penetration.

  • Development of bispecific antibodies targeting SSTR4 and other signaling components simultaneously.

  • Engineering of intracellularly-expressed antibody fragments for tracking SSTR4 in living cells.

• Adaptation of Synthetic Anti-RNA Technology:

  • Implementation of "sarabody" technology for visualization of SSTR4 mRNA in living cells .

  • Creation of antibody-based probes that can simultaneously track SSTR4 at both RNA and protein levels .

  • Development of orthogonal probe sets for multiplex imaging of different somatostatin receptors .

• Therapeutic Antibody Engineering:

  • Rational design of antibodies targeting specific SSTR4 epitopes for therapeutic applications .

  • Optimization of antibody properties to enhance efficacy against emerging variants .

  • Creation of antibody derivatives with improved pharmacokinetics and tissue distribution.

These innovative approaches could overcome current limitations in SSTR4 research tools and enable previously challenging investigations of receptor biology and function.

What are the potential therapeutic applications of SSTR4 antibodies in development?

SSTR4 antibodies show promise for several therapeutic applications that could translate basic research findings into clinical benefits:

• Cancer Therapeutics:

  • Development of SSTR4-targeting antibodies that exploit its antiproliferative functions in tumor cells .

  • Creation of antibody-drug conjugates for selective delivery of cytotoxic payloads to SSTR4-expressing tumors.

  • Combination therapies leveraging SSTR4 signaling to enhance standard-of-care treatments.

• Anti-inflammatory Applications:

  • Exploitation of SSTR4's anti-inflammatory properties through agonistic antibodies.

  • Development of therapies for inflammatory bowel disease, rheumatoid arthritis, and other inflammatory conditions.

  • Creation of antibodies with improved tissue penetration for targeting inflammation in privileged sites.

• Neurological Disorder Treatments:

  • Engineering of blood-brain barrier-penetrating antibodies targeting SSTR4 in the CNS.

  • Development of neuroprotective strategies based on SSTR4's role in neurotransmission.

  • Potential applications in pain management, neurodegenerative diseases, and seizure disorders.

• Diagnostic Applications:

  • Creation of imaging agents based on SSTR4 antibodies for tumor visualization.

  • Development of companion diagnostics to identify patients likely to respond to SSTR4-targeted therapies.

  • Implementation of theranostic approaches combining diagnostic and therapeutic functions.

Advances in antibody engineering, including preemptive optimization strategies to enhance therapeutic efficacy , are accelerating the development of these potential clinical applications.

How can researchers implement cutting-edge analytical methods to characterize SSTR4 antibodies?

Advanced analytical techniques enable comprehensive characterization of SSTR4 antibodies for research and therapeutic applications:

• Mass-Based Analytical Approaches:

  • Mass photometry (MP) provides a sensitive method for characterizing antibody-SSTR4 interactions and determining binding stoichiometries .

  • Native mass spectrometry (MS) delivers excellent mass resolution and accuracy, particularly valuable for analyzing antibody-antigen complexes .

  • Single-particle charge detection MS can accurately determine masses of heterogeneous assemblies, including heavily glycosylated forms of SSTR4 .

• Advanced Binding Kinetics Assessment:

  • Biolayer interferometry (BLI) enables real-time analysis of antibody-SSTR4 binding kinetics without labeling .

  • Surface plasmon resonance (SPR) provides detailed binding affinity measurements and epitope mapping capabilities.

  • Microscale thermophoresis (MST) allows binding studies in complex biological solutions with minimal sample consumption.

• Structural Characterization Methods:

  • Cryo-electron microscopy for visualizing antibody-SSTR4 complexes at near-atomic resolution.

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS) for mapping antibody binding epitopes on SSTR4.

  • Small-angle X-ray scattering (SAXS) for analyzing antibody-receptor complex conformations in solution.

• Functional Screening Platforms:

  • High-content imaging systems for screening antibody effects on SSTR4 trafficking and signaling.

  • CRISPR-based genetic screens to identify factors influencing antibody-SSTR4 interactions.

  • Advanced reporter assays for quantifying functional impacts of antibody binding on SSTR4 signaling.

These sophisticated analytical methods provide unprecedented insights into antibody-receptor interactions, facilitating the development of improved research tools and potential therapeutics targeting SSTR4.